UCB SA (OTCMKTS:UCBJY) Sees Large Growth in Short Interest

UCB SA (OTCMKTS:UCBJY - Get Free Report) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 30,700 shares, a growth of 859.4% from the March 31st total of 3,200 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 133,100 shares, the short-interest ratio is currently 0.2 days.

UCB Stock Performance

UCB stock traded up $3.31 during trading hours on Tuesday, hitting $89.11. The company had a trading volume of 48,226 shares, compared to its average volume of 44,222. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. UCB has a one year low of $63.58 and a one year high of $106.60. The firm has a 50-day moving average of $89.70 and a 200 day moving average of $94.14.

UCB Increases Dividend

The business also recently declared a dividend, which will be paid on Wednesday, May 14th. Shareholders of record on Tuesday, April 29th will be issued a $0.4838 dividend. This is a boost from UCB's previous dividend of $0.46. This represents a yield of 0.62%. The ex-dividend date of this dividend is Monday, April 28th.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.